# Surgical management of hypertrophic cardiomyopathy

**Authors:** Chandrasekaran Ananthanarayanan, SriKrishna Reddy Modugula, Vincent Chauvette, Daniel Ragheb, Rohun Bhagat, Nicholas Smedira

PMC · DOI: 10.1007/s12055-026-02180-1 · Indian Journal of Thoracic and Cardiovascular Surgery · 2026-01-26

## TL;DR

Surgical myectomy is an effective treatment for hypertrophic cardiomyopathy, significantly reducing symptoms and improving survival.

## Contribution

A detailed analysis of 1549 HCM patients who underwent surgical myectomy at the Cleveland Clinic from 2005 to 2015.

## Key findings

- Surgical myectomy reduced the mean left ventricular outflow tract gradient from 63 mmHg to 15 mmHg.
- Operative mortality was 0.38% with a mean hospital stay of 6 days.
- Most patients achieved New York Heart Association class I post-operatively.

## Abstract

Hypertrophic cardiomyopathy (HCM) is a dynamic disease with a spectrum of clinical presentations ranging from incidental diagnosis to sudden cardiac death. Symptomatic patients are initially managed medically, and newer drugs are currently under investigation. Invasive therapy is needed for patients with intractable symptoms despite maximal medical therapy, and surgical myectomy is the gold standard treatment with better long-term survival.

Over three decades, more than 4000 patients underwent surgical myectomy at the Cleveland Clinic. We conducted a detailed analysis of patients who underwent surgery for HCM between 2005 and 2015. Within this study period, 1549 patients underwent surgical myectomy. Their mean pre-operative peak left ventricular outflow tract (LVOT) gradient was 63 ± 4.6 mmHg, and it reduced to 15 ± 8.9 mmHg after surgery. Mean aortic cross-clamp time was 28 ± 10 min for isolated septal myectomy, and the mean mass of muscle resected was 8.1 ± 3.7 g. Complications include new incidences of pacemaker insertion in 4.2% of the patients, iatrogenic ventricular septal defects in two patients, and the overall operative mortality was 0.38%. Mean hospital stay was 6 days, and the majority of the patients are in New York Heart Association (NYHA) class I in their post-operative follow-up.

Septal myectomy is a curative therapy for most patients of HCM who are symptomatic despite maximal medical management. Clear understanding of individual septal anatomy and mechanisms of LVOT obstruction are key to successful surgical outcomes. Septal myectomy can be done safely with excellent long-term results.

## Linked entities

- **Diseases:** hypertrophic cardiomyopathy (MONDO:0005045), sudden cardiac death (MONDO:0007264)

## Full-text entities

- **Diseases:** HCM (MESH:D002312), sudden cardiac death (MESH:D016757), ventricular septal defects (MESH:D006345), LVOT obstruction (MESH:D000092242)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12847563/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12847563/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12847563/full.md

---
Source: https://tomesphere.com/paper/PMC12847563